Ascentage Pharma Group International (AAPG) Stock Forecast
AAPG analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.70 / 5 from 10 analysts
- Price target
- $43.27 average of analyst targets
- Upside to target
- +181.5% from the latest close
- Next earnings
- —
- 52-week range
- $14.55 – $35.46
AAPG analyst ratings
10 analystsNumber of analysts at each rating.
AAPG price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AAPG earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.56 | −$0.62 | −$0.50 | — | — | 2 |
| Current fiscal year (2026) | −$1.18 | −$2.38 | −$0.57 | −$2.00 | +41.1% | 6 |
| Next fiscal year (2027) | −$0.65 | −$2.05 | $0.04 | −$1.18 | +45.1% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AAPG revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $178.3M | $164.6M | $192.0M | — | 2 |
| Current fiscal year (2026) | $677.6M | $614.1M | $879.4M | +18.0% | 9 |
| Next fiscal year (2027) | $1.44B | $743.5M | $2.72B | +111.9% | 11 |
AAPG EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AAPG revenue: reported and forecast
AAPG EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.48 | −$0.48 | −$0.62 | −$0.62 | −$0.56 | +16.8% | 0 up · 1 down |
| Current fiscal year (2026) | −$1.52 | −$1.52 | −$1.19 | −$1.03 | −$1.18 | −22.3% | 0 up · 2 down |
| Next fiscal year (2027) | −$1.19 | −$1.19 | −$1.04 | −$0.77 | −$0.65 | −45.6% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AAPG earnings surprises
Reported EPS vs the consensus estimate for the last 4 quarters; AAPG beat in 2 of 4.
What analysts expect from AAPG
10 analysts cover Ascentage Pharma Group International; their consensus rating is strong buy (4.70 on a 1–5 scale, where 5 is a strong buy). The average price target is $43.27, 181.5% above the latest close of $15.37. Analysts expect earnings of −$1.18 per share for 2026, +41.1% from a year earlier. For 2027 the average estimate is −$0.65 per share on revenue of $1.4 billion. Ascentage Pharma Group International beat the EPS estimate in 2 of the last 4 quarters.
Related: AAPG income statement, AAPG key metrics, AAPG chart. See the AAPG stock overview for the latest quote and news.
AAPG forecast FAQ
What is Ascentage Pharma Group International's price target?
The average analyst price target for Ascentage Pharma Group International is $43.27, 181.5% above the latest close of $15.37.
Is Ascentage Pharma Group International a buy, hold or sell?
Of 10 analysts covering Ascentage Pharma Group International, 7 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Ascentage Pharma Group International's EPS forecast?
Analysts forecast −$1.18 per share for 2026 (range −$2.38 to −$0.57); for 2027 the estimate is −$0.65.
What is Ascentage Pharma Group International's revenue forecast?
The average revenue estimate for 2026 is $677.6 million, growth of 18.0%; for 2027 it is $1.4 billion.
Does Ascentage Pharma Group International usually beat earnings estimates?
Ascentage Pharma Group International reported EPS at or above the analyst estimate in 2 of the last 4 quarters.